araag2/HINT huggingface dataset:
Clinical trial NCT02462928 (phase 3, status: completed)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: abicipar pegol, ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of age-related macular degeneration in at least 1 eye

          -  Best corrected visual acuity of 20/40 to 20/320 in the study eye

          -  Best corrected visual acuity of 20/200 or better in the non-study eye

        Exclusion Criteria:

          -  History of vitrectomy, macular surgery, or glaucoma surgery in the study eye

          -  Cataract or refractive surgery in the study eye within the last 3 months
Clinical trial NCT02469155 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: iti-007, risperidone, placebo
SMILES: [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis
             of schizophrenia

          -  experiencing an acute exacerbation of psychosis

        Exclusion Criteria:

          -  any subject unable to provide informed consent

          -  any female subject who is pregnant or breast-feeding

          -  any subject judged to be medically inappropriate for study participation
Clinical trial NCT02472886 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participants who failed treatment in Study GS-US-334-0119 who meet relevant
             inclusion/exclusion criteria are eligible for retreatment in this study

          -  Chronic genotype 1 HCV infection

          -  HCV treatment-naive

          -  HCV RNA > 10,000 IU/mL at screening

          -  Absence of cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Key Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Infection with hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with the individual's treatment, assessment, or compliance with the protocol

          -  For HIV-1/HCV co-infected individuals:

               -  Opportunistic infection within 6 months prior to screening

               -  Active, serious infection (other than HIV-1 or HCV) requiring parental
                  antibiotics, antivirals or antifungals within 30 days prior to baseline

               -  Treatment with an antiretroviral (ARV) regimen other than one of those listed in
                  the study protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02473198 (phase 3, status: unknown status)
Conditions: osteoarthritis, pain
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: exparel, femoral nerve block bupivacaine, toradol, morphine sulfate
SMILES: O=[Zn], CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1, [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Eligibility criteria:

        Inclusion Criteria:

        • Patients between the ages of 18 - 73 who are undergoing primary, unilateral, Total Knee
        Replacement at the New England Baptist Hospital in Boston, Massachusetts are eligible to
        participate.

        Exclusion Criteria:

          -  Patients with Revision or Complex Total Knee Replacements and are under the age of 18,
             or over the age of 73 will be excluded.

          -  Patients with an ASA 4 level will be excluded.

          -  Patients with a Body Mass Index of less than 20, and over 40, will be excluded.

          -  Patients taking preoperative narcotics, patients with extreme sensitivity or allergy
             to narcotics or local anesthetics, and patients using opioid medications for at least
             3 months leading up to surgery, will also be excluded.
Clinical trial NCT02474082 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: fumaric acid
SMILES: OC(=O)\C=C\C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women must be at least 18 years of age at the time of screening

          -  Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization
             Patients with moderate to severe plaque psoriasis who are candidates for systemic
             therapy as defined at randomization by:

          -  PASI score of >10

          -  Affected body surface area (BSA) > 10%

          -  DLQI >10

          -  Inadequate response, intolerance or contraindication to topical psoriasis treatment as
             documented in the patient's medical history or reported by the patient or determined
             by the investigator at screening.

        Exclusion Criteria (abbreviated):

          -  Previous systemic treatment of plaque psoriasis or known contraindication for systemic
             therapy at baseline

          -  Ongoing use of other prohibited psoriasis and non-psoriasis treatment.

          -  Clinically important active infections or infestations, chronic, recurrent or latent
             infections or infestations

          -  Patients with severe liver diseases

          -  Patients with severe gastrointestinal diseases including but not limited to
             ventricular and duodenal ulcers

          -  Patients with severe kidney diseases or serum creatinine above 1 x ULN

          -  Patients with known hematological disease or lab abnormalities

          -  Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of
             contraception (if necessary)
Clinical trial NCT02475681 (phase 3, status: active, not recruiting)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: acalabrutinib, obinutuzumab, chlorambucil
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women: ≥ 65 years of age OR > 18 and < 65 years of age, provided that they
             meet at least one of the following criteria:

               1. Creatinine clearance 30 to 69 mL/min.

               2. A score higher than 6 on the Cumulative Illness Rating Scale-Geriatric.

          -  ECOG performance status of 0, 1, or 2.

          -  Diagnosis of CD20+ CLL.

          -  Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring
             treatment.

          -  Meet the following laboratory parameters:

               1. ANC ≥ 750 cells/μL, or ≥ 500 cells/μL in subjects with documented bone marrow
                  involvement, and independent of growth factor support 7 days before assessment.

               2. Platelet count ≥ 50,000 cells/μL, or ≥ 30,000 cells/μL in subjects with
                  documented bone marrow involvement, and without transfusion support 7 days before
                  assessment. Subjects with transfusion-dependent thrombocytopenia are excluded.

               3. Serum AST and ALT/SGPT ≤ 3.0 x ULN.

               4. Total bilirubin ≤ 1.5 x ULN.

               5. Estimated creatinine clearance ≥ 30 mL/min.

        Exclusion Criteria:

          -  Any prior systemic treatment for CLL.

          -  Known CNS lymphoma or leukemia.

          -  Known prolymphocytic leukemia or history of, or currently suspected, Richter's
             syndrome.

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

          -  Major surgery within 4 weeks before first dose of study drug.

          -  Prior malignancy, except for adequately treated lentigo maligna melanoma,
             non-melanomatous skin cancer, in situ cervical carcinoma, or other malignancy treated
             with no evidence of active disease > 3 years before Screening and at low risk for
             recurrence.

          -  Significant cardiovascular disease within 6 months of screening.

          -  Known history of infection with HIV.

          -  History of stroke or intracranial hemorrhage within 6 months before randomization.

          -  Known history of a bleeding diathesis.

          -  Requires or receiving anticoagulation with warfarin or equivalent vitamin K
             antagonists within 7 days of first dose of study drug.
Clinical trial NCT02477618 (phase 3, status: completed)
Conditions: super-refractory status epilepticus
ICD codes: G40.803, G40.804, G40.823, G40.824, G40.833, G40.834, G40.911
Drugs: sage-547, placebo
SMILES: [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects two (2) years of age and older

          -  Subjects who have:

               -  Failed to respond to the administration of at least one first-line agent (e.g.,
                  benzodiazepine or other emergent initial anti-epileptic drug [AED] treatment),
                  according to institution standard of care, and;

               -  Failed to respond to at least one second-line agent (e.g., phenytoin,
                  fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control
                  AED), according to institution standard of care, and;

               -  Not previously been administered a third-line agent but have been admitted to an
                  intensive care unit with the intent of administering at least one third-line
                  agent for at least 24 hours; or who have previously failed zero, one or more wean
                  attempts from third-line agents and are now on continuous intravenous infusions
                  of one or more third-line agent and in an EEG burst or seizure suppression
                  pattern; or who have previously failed one or more wean attempts from third-line
                  agents and are now either not on a continuous intravenous infusion of at least
                  one third-line agent or are on a continuous intravenous infusion of one or more
                  third-line agent but not in an EEG burst or seizure suppression pattern

        Exclusion Criteria:

          -  Subjects with SRSE due to anoxic/hypoxic encephalopathy with highly malignant/
             malignant EEG features

          -  Children (subjects aged less than 17 years) with an encephalopathy due to a rapidly
             progressing underlying neurological disorder

          -  Subjects who have any of the following:

               1. a glomerular filtration rate (GFR) low enough to warrant dialysis but for
                  whatever reason, dialysis is not planned or non-continuous dialysis planned (that
                  would not adequately remove Captisol®);

               2. severe cardiogenic or vasodilatory shock requiring two or more pressors that is
                  not related to third-line agent use;

               3. fulminant hepatic failure;

               4. no reasonable expectation of recovery (for instance, a likely outcome is
                  persistent vegetative state) or life-expectancy, in the experience of the
                  investigator, is less than 30 days.

          -  Subjects who are being administered more than three third-line agents concomitantly or
             in whom the qualifying wean cannot be completed per protocol
Clinical trial NCT02477800 (phase 3, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: aducanumab (biib037), aducanumab (biib037), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study was discontinued based on futility analysis done and not based on safety concerns.
    follow-up visits and closing out study activities are completed
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must meet all of the following clinical criteria for MCI due to AD or mild AD and must
             have:

          -  A Clinical Dementia Rating (CDR)-Global Score of 0.5.

          -  Objective evidence of cognitive impairment at screening

          -  An MMSE score between 24 and 30 (inclusive)

          -  Must have a positive amyloid Positron Emission Tomography (PET) scan

          -  Must consent to apolipoprotein E (ApoE) genotyping

          -  If using drugs to treat symptoms related to AD, doses must be stable for at least 8
             weeks prior to screening visit 1

          -  Must have a reliable informant or caregiver

        Key Exclusion Criteria:

          -  Any medical or neurological condition (other than Alzheimer's Disease) that might be a
             contributing cause of the subject's cognitive impairment

          -  Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of
             consciousness in the past 1 year

          -  Clinically significant unstable psychiatric illness in past 6 months

          -  History of unstable angina, myocardial infarction, advanced chronic heart failure, or
             clinically significant conduction abnormalities within 1 year prior to Screening

          -  Indication of impaired renal or liver function

          -  Have human immunodeficiency virus (HIV) infection

          -  Have a significant systematic illness or infection in past 30 days

          -  Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities

          -  Any contraindications to brain magnetic resonance imaging (MRI) or PET scans

          -  Alcohol or substance abuse in past 1 year

          -  Taking blood thinners (except for aspirin at a prophylactic dose or less)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT02480712 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  HCV RNA ≥ 10^4 IU/mL at screening

          -  HCV genotype 1, 2, 3, 4, 5, 6

          -  Cirrhosis determination, a fibroscan or liver biopsy may be required

          -  HIV-1 infection

          -  Use of protocol specified method(s) of contraception

          -  Screening laboratory values within defined thresholds

        Key Exclusion Criteria:

          -  Clinically-significant illness (other than HCV or HIV) or any other major medical
             disorder that may interfere with individual's treatment, assessment or compliance with
             the protocol

          -  Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma
             (HCC) or other malignancy (with the exception of certain resolved skin cancers)

          -  Screening ECG with clinically significant abnormalities

          -  Pregnant or nursing female or male with pregnant female partner

          -  Infection with hepatitis B virus (HBV)

          -  Use of any prohibited concomitant medications as described in the protocol

          -  Chronic use of systemically administered immunosuppressive agents

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02481830 (phase 3, status: active, not recruiting)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: nivolumab, topotecan, amrubicin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologically or cytologically confirmed small cell lung cancer (SCLC)

          -  Subjects with either limited or extensive disease stage at the initial diagnosis

          -  Must have recurrence or progression after platinum-based first-line chemotherapy or
             chemoradiation therapy for the treatment of limited or extensive disease stage SCLC

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Untreated or symptomatic central nervous system (CNS) metastases

          -  Prior therapy with anti-PD-1, anti-PDL1, anti-PD-L2, anti-CD137, or anti-CTLA-4
             antibody

          -  Inadequate hematologic or hepatic function
Clinical trial NCT02483585 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: erenumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of migraines (with or without aura) for ≥ 12 months

          -  Migraine frequency: ≥ 4 and < 15 migraine days per month on average acrossthe 3 months
             prior to screening

          -  Headache (ie, migraine and non-migraine headache) frequency: < 15 headache days per
             month on average across the 3 months prior to screening

          -  Demonstrated compliance with the eDiary

        Exclusion Criteria:

          -  Older than 50 years of age at migraine onset.

          -  History of cluster headache or hemiplegic migraine headache.

          -  Unable to differentiate migraine from other headaches

          -  No therapeutic response with > 2 categories for prophylactic treatment of migraine
             after an adequate therapeutic trial.

          -  Concomitant use of 2 or more medications with possible migraine prophylactic effects
             within 2 months prior to the start of the baseline phase or during the baseline phase.
             If only 1 prophylactic medication is used, the dose must be stable within 2 months
             prior to the start of the baseline phase and throughout the study

          -  Used a prohibited medication, device, or procedure within 2 months prior to the start
             of the baseline phase or during the baseline phase.

          -  Received botulinum toxin

          -  Anticipated to require any excluded medication, device, or procedure during the study.

          -  Active chronic pain syndromes (such as fibromyalgia and chronic pelvic pain).

          -  History of major psychiatric disorder.

          -  History of seizure disorder or other significant neurological conditions other than
             migraine.

          -  Human immunodeficiency virus (HIV) infection by history.

          -  Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina,
             or coronary artery bypass surgery or other revascularization procedure within 12
             months prior to screening.

          -  The subject is at risk of self-harm or harm to others. Previously randomized into an
             AMG 334 study.

          -  Unlikely to be able to complete all protocol required study visits or procedures,
             and/or to comply with all required study procedures.
Clinical trial NCT02484001 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: esl 800 mg, esl 1200 mg, esl 1600 mg, esl 400 mg
SMILES: CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

        For inclusion in the extension study, subjects must fulfill all of the following at Visit 1
        (Day 1, start of the open-label extension study):

          1. Participated in the preceding double-blind study and were still ongoing at the time of
             unblinding.

          2. Have signed informed consent before undergoing any activities related to the
             open-label extension study.

          3. Demonstrated cooperation and willingness to complete all aspects of the study.

          4. Female subjects without childbearing potential (2 years postmenopausal, bilateral
             oophorectomy or tubal ligation, or complete hysterectomy) are eligible. Female
             subjects with childbearing potential must not be pregnant as confirmed by a negative
             serum ß-human chorionic gonadotropin (hCG) test and sexually active females must be
             using a medically acceptable effective non-hormonal method of contraception for the
             duration of the study and until the Post-study Visit (PSV).

        Exclusion Criteria:

        Subjects having any of the following at Visit 1 are to be excluded from the study:

          1. Excluded from the double-blind study due to seizure in the Maintenance or Extension
             Phase, or at dose level C (either CBZ-CR or ESL), or discontinued prematurely due to
             any other reason in the double-blind study.

          2. Presence of any major protocol violation during the double-blind study which may have
             an impact on the compliance during this extension study.

          3. Judged clinically to have a suicidal risk in the opinion of the investigator based
             upon a clinical interview and the Columbia Suicide-Severity Rating Scale (C-SSRS).

          4. Occurrence of an adverse event (AE) indicating a suspected presence of
             atrioventricular block (2nd degree and above) or of any other AEs during the
             double-blind study which are judged by the investigator as contraindicative to further
             participation in the open-label extension study.

          5. Events of alcohol, drug, or medication abuse during the preceding double-blind study.

          6. Relevant clinical laboratory abnormalities (e.g. sodium <125 mmol/L, alanine or
             aspartate transaminases >2 x the upper limit of normal, white blood cell count <3000
             cells/mm3) (as reported at Visit 1).

          7. Pregnancy or lactating.

          8. Any other condition or circumstance that, in the opinion of the investigator, could
             compromise the subject's ability to comply with the extension-study protocol.